Recurring Revenue StreamsRecurring service, maintenance and training contracts provide durable revenue and higher customer retention. These annuity-like streams improve revenue visibility, support margins over time, and reduce sensitivity to single-device sales fluctuations, aiding 2-6 month cash planning.

Diversified Product PortfolioA broad offering across instruments, robotics and imaging across orthopedics, cardiology and general surgery spreads commercial risk. This multi-therapy exposure supports steadier demand cycles and cross-selling opportunities, strengthening medium-term revenue resilience.

Go-to-Market And Research PartnershipsCombining direct sales with distributor networks expands market reach and scalability while research and hospital alliances accelerate clinical validation and product development. These structural channels sustain market access and pipeline progress over the medium term.

Bears Say

Declining RevenueA sustained revenue decline reduces scale benefits and weakens the company’s ability to absorb fixed costs. Over several quarters this pressures investment in R&D and commercialization, eroding competitiveness and making recovery more dependent on new product traction.

Persistent Losses And Negative MarginsRepeated operating losses and negative EBIT/EBITDA indicate structural profitability issues, whether pricing, mix, or cost base. These losses constrain cash generation and reinvestment, increasing reliance on external funding and raising execution risk for strategic initiatives.

Balance Sheet WeaknessNegative shareholders' equity means liabilities exceed assets, signaling high leverage and limited financial flexibility. This elevates refinancing and covenant risk, potentially restricting capital for product development, clinical trials, or sales expansion over the medium term.

ASTI FAQ

What was Aquarius Surgical Technologies Inc.’s price range in the past 12 months?

Aquarius Surgical Technologies Inc. lowest stock price was C$0.01 and its highest was C$0.03 in the past 12 months.

What is Aquarius Surgical Technologies Inc.’s market cap?

Aquarius Surgical Technologies Inc.’s market cap is C$275.99K.

When is Aquarius Surgical Technologies Inc.’s upcoming earnings report date?

Aquarius Surgical Technologies Inc.’s upcoming earnings report date is Mar 03, 2026 which is in 9 days.

How were Aquarius Surgical Technologies Inc.’s earnings last quarter?

Aquarius Surgical Technologies Inc. released its earnings results on Dec 01, 2025. The company reported -C$0.029 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.029.

Is Aquarius Surgical Technologies Inc. overvalued?

According to Wall Street analysts Aquarius Surgical Technologies Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Aquarius Surgical Technologies Inc. pay dividends?

Aquarius Surgical Technologies Inc. does not currently pay dividends.

What is Aquarius Surgical Technologies Inc.’s EPS estimate?

Aquarius Surgical Technologies Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Aquarius Surgical Technologies Inc. have?

Aquarius Surgical Technologies Inc. has 27,599,173 shares outstanding.

What happened to Aquarius Surgical Technologies Inc.’s price movement after its last earnings report?

Aquarius Surgical Technologies Inc. reported an EPS of -C$0.029 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Aquarius Surgical Technologies Inc.?

Currently, no hedge funds are holding shares in TSE:ASTI

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Aquarius Surgical Technologies Inc.

Aquarius Surgical Technologies (ASTI) is a pioneering company in the medical device sector, specializing in advanced surgical solutions designed to enhance patient outcomes and streamline surgical procedures. The company focuses on developing innovative technologies for minimally invasive surgeries, including a range of surgical instruments, robotic systems, and imaging solutions that cater to various medical fields such as orthopedics, cardiology, and general surgery. ASTI is committed to improving surgical efficiency and safety through its cutting-edge products and comprehensive support services.